BELFA vs WRD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BELFA's Advanced Deterministic Scorecard reveals weak financial health with a Piotroski F-Score of 3/9, indicating significant concerns in profitability, leverage, and operating efficiency. Despite this, the company exhibits strong recent growth, with 44.80% YoY revenue growth and 172.90% earnings growth, supported by consistent earnings beats and high profitability margins. Valuation appears stretched at a P/E of 37.63 versus a Graham Number of $60.47, though sector context (avg P/E 93.05) suggests relative reasonableness. The lack of Altman Z-Score and analyst coverage, combined with weak insider sentiment and deteriorating technical trend, offsets strong fundamentals and growth momentum.
WRD presents a classic high-growth, high-burn profile with a Piotroski F-Score of 4/9, indicating stable but fragile financial health. While the company exhibits explosive revenue growth (123% YoY) and maintains a fortress-like balance sheet with a Current Ratio of 8.20 and negligible debt, these are offset by severe operating losses and a profit margin of -241.74%. There is a stark divergence between the strong analyst consensus (Strong Buy, $14.09 target) and the bearish technical trend (0/100), suggesting a speculative environment where fundamental growth is fighting short-term market sentiment.
Compare Another Pair
Related Comparisons
BELFA vs WRD: Head-to-Head Comparison
This page compares Bel Fuse Inc. (BELFA) and WeRide Inc. (WRD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.